What are reps actually earning at the industry’s biggest companies? Which specialties are reporting the highest paychecks? And does experience guarantee higher compensation?

This week, we’re digging into our anonymous compensation data, examining a major leadership transition at Stryker, and looking at what it takes to reach $300K in medical device sales.

A $200K W-2 might be considered exceptional in one medical device specialty and relatively ordinary in another.

The company, division, territory, experience level, and commission structure can all dramatically change what a rep takes home.

We’re continuing to analyze anonymous compensation reports submitted to The Med Device Rep, and some interesting patterns are emerging.

1. Medtronic leads this group in reported $200K+ earnings.

Three out of four Medtronic respondents reported earning at least $200K.

However, Stryker and Medtronic reported identical percentages earning $300K or more.

2. Compensation varies dramatically within the same company.

At Stryker, reported compensation ranged from $75K to more than $400K.

That’s an enormous difference under one corporate umbrella.

It reinforces why comparing compensation without considering division, position, and territory can be misleading.

3. Company name alone doesn’t determine earning potential.

The data suggests that specialty and role can matter just as much as the employer.

Which brings us to the next question.

Spine leads the way, with 67% reporting $300K+ in W-2 earnings. Capital equipment also stands out, with 78% reporting $200K+.

Sports medicine and general orthopedics came in considerably lower.

Specialty sample sizes remain relatively small, and factors like experience, geography, role, and territory opportunity can significantly influence earnings.

Not necessarily.

Only 45% of respondents who answered said they feel fairly compensated. The other 55% said no or weren’t sure.

One rep reported a 20% quota increase while expecting to earn roughly $70K less. Another reported expanding from one state to three with only a 5% increase in compensation.

The recurring theme: Growing the business doesn’t always mean growing your paycheck.

Want to see how your compensation compares?

The market looks very different heading into the final months of 2026.

But opportunities are still taking shape.

MarketBeat’s free report 10 Best Stocks to Own in Fall 2026 highlights 10 companies positioned around some of today’s strongest trends, including AI infrastructure, cloud computing, energy, dividends, share buybacks and consumer growth.

One has more than $650 billion in contracted future business. Another recently posted triple-digit revenue growth. A third saw quarterly revenue climb more than 165%.

These aren’t all high-flying tech stocks, either.

Get your complimentary copy of the full report today before it goes back behind the paywall.

Get the Free Report

After more than 14 years as CEO, Kevin Lobo is preparing to hand over leadership of Stryker.

On January 1, 2027, Lobo will transition to executive chair, while current president and COO Spencer Stiles will become CEO.

When Lobo became CEO in 2012, Stryker generated approximately $8.7 billion in annual sales. Today, annual sales exceed $26 billion.

During his tenure, Stryker completed more than 60 acquisitions while expanding aggressively into robotics and new areas of medtech.

Stiles, meanwhile, is a nearly three-decade Stryker veteran who has led businesses across Orthopaedics, MedSurg and Neurotechnology.

Probably continuity more than immediate disruption.

But three areas are worth watching:

Acquisitions: Does Stryker maintain its aggressive approach to expanding the portfolio?

Robotics: Does investment in technology-driven surgical platforms accelerate?

Sales strategy: As the portfolio expands, how does Stryker balance specialization with cross-divisional selling?

A leadership transition at one of medtech’s largest companies deserves attention, but with a longtime internal executive taking over, this looks more like the next chapter of Stryker’s existing strategy than a reset.

BD Announces $19 Billion U.S. Investment Commitment

BD announced plans to invest $19 billion in U.S. manufacturing and operations, including previously announced investments. The move reflects growing pressure across medtech to strengthen domestic supply chains.

Boston Scientific Files Patent Lawsuit Against J&J Subsidiary

Boston Scientific filed a patent infringement lawsuit against J&J subsidiary Atraverse Medical involving cardiac technology. The dispute highlights the increasingly competitive cardiovascular device market.

Everyone wants to know which medical device specialties offer the biggest earning potential.

But there’s another question worth asking:

How long does it actually take to reach $300K?

Our compensation data offers an interesting look at how reported earnings change with experience.

Reported earnings increase substantially with experience, particularly during the first 15 years.

But the highest percentage of $300K earners isn’t among respondents with 20-plus years of experience.

It’s among those with 11 to 15 years.

That doesn’t prove earnings peak at that point. The groups differ in size and composition, and the survey captures only one point in time.

Still, it raises an important question.

Is earning potential determined more by experience or by the opportunities you pursue along the way?

A rep with ten years of experience in a high-performing territory may earn substantially more than someone with twenty years in a less lucrative role.

The lesson isn’t to chase the highest advertised OTE.

It’s to understand the actual earning opportunity.

1. What did the previous territory manager actually earn?

Advertised OTE and historical W-2 earnings can tell very different stories.

2. What percentage of the sales organization achieved quota last year?

A $300K OTE means little if almost nobody reaches it.

3. What happens to my compensation when the territory grows?

Understand quota increases, commission accelerators, caps, and compensation-plan changes before accepting an offer.

The best-paying opportunity isn’t always the company with the biggest name.

It’s the opportunity where your performance has the greatest potential to translate into earnings.

Medical device compensation has historically been difficult to compare.

We’re working to change that by collecting anonymous, firsthand compensation reports across the industry.

If you haven’t contributed yet, your experience can help other reps make more informed career decisions.

Know another medical device professional who would find this useful?

Forward them this issue.

See you next week,

The Med Device Rep

Compensation data is self-reported, unverified, and drawn from a voluntary, nonrepresentative sample. Figures should not be interpreted as company-wide or national compensation benchmarks.